280 related articles for article (PubMed ID: 27442378)
1. New Therapies for Hepatitis C Virus.
Polenakovik H
Pril (Makedon Akad Nauk Umet Odd Med Nauki); 2015; 36(2):119-32. PubMed ID: 27442378
[TBL] [Abstract][Full Text] [Related]
2. Drug Pricing Evolution in Hepatitis C.
Vernaz N; Girardin F; Goossens N; Brügger U; Riguzzi M; Perrier A; Negro F
PLoS One; 2016; 11(6):e0157098. PubMed ID: 27310294
[TBL] [Abstract][Full Text] [Related]
3. New hepatitis C therapies: the toolbox, strategies, and challenges.
Pawlotsky JM
Gastroenterology; 2014 May; 146(5):1176-92. PubMed ID: 24631495
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of generic pan-genotypic sofosbuvir/velpatasvir versus genotype-dependent direct-acting antivirals for hepatitis C treatment.
Goel A; Chen Q; Chhatwal J; Aggarwal R
J Gastroenterol Hepatol; 2018 Dec; 33(12):2029-2036. PubMed ID: 29864213
[TBL] [Abstract][Full Text] [Related]
5. Hepatitis C treatment in the elderly: New possibilities and controversies towards interferon-free regimens.
Vespasiani-Gentilucci U; Galati G; Gallo P; De Vincentis A; Riva E; Picardi A
World J Gastroenterol; 2015 Jun; 21(24):7412-26. PubMed ID: 26139987
[TBL] [Abstract][Full Text] [Related]
6. [Progress in Examination and Treatment of Hepatitis C Virus].
Suda G; Sakamoto N
Rinsho Byori; 2015 Jun; 63(6):762-7. PubMed ID: 26548242
[TBL] [Abstract][Full Text] [Related]
7. Should we await IFN-free regimens to treat HCV genotype 1 treatment-naive patients? A cost-effectiveness analysis (ANRS 95141).
Deuffic-Burban S; Schwarzinger M; Obach D; Mallet V; Pol S; Pageaux GP; Canva V; Deltenre P; Roudot-Thoraval F; Larrey D; Dhumeaux D; Mathurin P; Yazdanpanah Y
J Hepatol; 2014 Jul; 61(1):7-14. PubMed ID: 24650691
[TBL] [Abstract][Full Text] [Related]
8. Future perspectives: towards interferon-free regimens for HCV.
Gane E
Antivir Ther; 2012; 17(6 Pt B):1201-10. PubMed ID: 23186654
[TBL] [Abstract][Full Text] [Related]
9. Newer direct-acting antivirals for hepatitis C virus infection: Perspectives for India.
Gupta V; Kumar A; Sharma P; Arora A
Indian J Med Res; 2017 Jul; 146(1):23-33. PubMed ID: 29168457
[TBL] [Abstract][Full Text] [Related]
10. Boceprevir and telaprevir in the management of hepatitis C virus-infected patients.
Butt AA; Kanwal F
Clin Infect Dis; 2012 Jan; 54(1):96-104. PubMed ID: 22156853
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis C virus: standard-of-care treatment.
Pawlotsky JM
Adv Pharmacol; 2013; 67():169-215. PubMed ID: 23886001
[TBL] [Abstract][Full Text] [Related]
12. Hepatitis C virus therapy with peg-interferon and ribavirin in Myanmar: A resource-constrained country.
Hlaing NK; Banerjee D; Mitrani R; Arker SH; Win KS; Tun NL; Thant Z; Win KM; Reddy KR
World J Gastroenterol; 2016 Nov; 22(43):9613-9622. PubMed ID: 27920482
[TBL] [Abstract][Full Text] [Related]
13. Asunaprevir-containing regimens for the treatment of hepatitis C virus infection.
Yang SS; Kao JH
Expert Rev Gastroenterol Hepatol; 2015 Jan; 9(1):9-20. PubMed ID: 25174254
[TBL] [Abstract][Full Text] [Related]
14. Current and future HCV therapy: do we still need other anti-HCV drugs?
Petta S; Craxì A
Liver Int; 2015 Jan; 35 Suppl 1():4-10. PubMed ID: 25529081
[TBL] [Abstract][Full Text] [Related]
15. [A new challenge in clinical practice: resistance to directly acting antivirals in hepatitis C treatment].
Chen ZW; Hu P; Ren H
Zhonghua Gan Zang Bing Za Zhi; 2016 Mar; 24(3):165-9. PubMed ID: 27095757
[TBL] [Abstract][Full Text] [Related]
16. [Anti-hepatitis C Virus Strategy Targeting the Entry Steps].
Fukasawa M
Yakugaku Zasshi; 2019; 139(1):89-95. PubMed ID: 30606936
[TBL] [Abstract][Full Text] [Related]
17. Interferon-Free Therapy for Hepatitis C in Liver Transplant Recipients.
Ueda Y; Uemoto S
Transplantation; 2016 Jan; 100(1):54-60. PubMed ID: 26335914
[TBL] [Abstract][Full Text] [Related]
18. New approaches in the treatment of hepatitis C.
González-Grande R; Jiménez-Pérez M; González Arjona C; Mostazo Torres J
World J Gastroenterol; 2016 Jan; 22(4):1421-32. PubMed ID: 26819511
[TBL] [Abstract][Full Text] [Related]
19. [Hepatitis C: diagnosis, anti-viral therapy, after-care. Hungarian consensus guideline].
Hunyady B; Gerlei Z; Gervain J; Horváth G; Lengyel G; Pár A; Rókusz L; Szalay F; Telegdy L; Tornai I; Werling K; Makara M
Orv Hetil; 2015 Mar; 156(9):343-51. PubMed ID: 25702254
[TBL] [Abstract][Full Text] [Related]
20. Prioritization of high-cost new drugs for HCV: making sustainability ethical.
Craxì L; Sacchini D; Refolo P; Minacori R; Daloiso V; Ricci G; Bruno R; Cammà C; Cicchetti A; Gasbarrini A; Spagnolo AG
Eur Rev Med Pharmacol Sci; 2016; 20(6):1044-51. PubMed ID: 27049255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
